{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:48:29Z","timestamp":1792824509701,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,19]]},"DOI":"10.7759\/cureus.18092","type":"journal-article","created":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T07:53:35Z","timestamp":1632038015000},"source":"Crossref","is-referenced-by-count":7,"title":["The Effectiveness of Statins as Potential Therapy for Multiple Sclerosis: A Systematic Review of Randomized Controlled trials"],"prefix":"10.7759","author":[{"given":"Mohammed A","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Zakhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiam","family":"Rushdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar A","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerolos N","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafreen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul P","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016, 86:1014-21. 10.1212\/WNL.0000000000002469","journal-title":"Neurology"},{"key":"ref2","article-title":"Multiple Sclerosis","author":"Tafti D","year":"2021","unstructured":"Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. StatPearls Publishing, Treasure Island, Florida; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0239-x","article-title":"Statin treatment in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Pihl-Jensen G","year":"2015","unstructured":"Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015, 29:277-91. 10.1007\/s40263-015-0239-x","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2007.08.004","article-title":"Statins--treatment option for central nervous system autoimmune disease?","volume":"4","author":"Weber MS","year":"2007","unstructured":"Weber MS, Steinman L, Zamvil SS. Statins--treatment option for central nervous system autoimmune disease?. Neurotherapeutics. 2007, 4:693-700. 10.1016\/j.nurt.2007.08.004","journal-title":"Neurotherapeutics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(98)00341-4","article-title":"Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro","volume":"57","author":"Suzumura K","year":"1999","unstructured":"Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol. 1999, 57:697-703. 10.1016\/s0006-2952(98)00341-4","journal-title":"Biochem Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021425","article-title":"Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin","volume":"197","author":"Aktas O","year":"2003","unstructured":"Aktas O, Waiczies S, Smorodchenko A, et al.. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003, 197:725-33. 10.1084\/jem.20021425","journal-title":"J Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef S","year":"2002","unstructured":"Youssef S, St\u00fcve O, Patarroyo JC, et al.. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420:78-84. 10.1038\/nature01158","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.9.5630","article-title":"Atorvastatin induces T cell anergy via phosphorylation of ERK1","volume":"174","author":"Waiczies S","year":"2005","unstructured":"Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol. 2005, 174:5630-5. 10.4049\/jimmunol.174.9.5630","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20875","article-title":"Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis","volume":"60","author":"Ifergan I","year":"2006","unstructured":"Ifergan I, Wosik K, Cayrol R, et al.. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006, 60:45-55. 10.1002\/ana.20875","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.7.990","article-title":"Statins as immunomodulators: comparison with interferon-beta 1b in MS","volume":"59","author":"Neuhaus O","year":"2002","unstructured":"Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 2002, 59:990-7. 10.1212\/wnl.59.7.990","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.043","article-title":"Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide","volume":"485","author":"Blume C","year":"2004","unstructured":"Blume C, Sabuda-Widemann D, Pfeilschifter J, Plum J, Schr\u00f6r K, Grabensee B, Beck KF. Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide. Eur J Pharmacol. 2004, 485:1-10. 10.1016\/j.ejphar.2003.11.043","journal-title":"Eur J Pharmacol"},{"key":"ref12","article-title":"Nitric oxide and superoxide in inflammation and immune regulation","volume":"54","author":"Guzik TJ","year":"2003","unstructured":"Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003, 54:469-87.","journal-title":"J Physiol Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1070-8","article-title":"Therapeutic potential of lovastatin in multiple sclerosis","volume":"250","author":"Sena A","year":"2003","unstructured":"Sena A, Pedrosa R, Gra\u00e7a Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003, 250:754-5. 10.1007\/s00415-003-1070-8","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer T","year":"2004","unstructured":"Vollmer T, Key L, Durkalski V, et al.. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004, 363:1607-8. 10.1016\/S0140-6736(04)16205-3","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001928","article-title":"Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis","volume":"3","author":"Paul F","year":"2008","unstructured":"Paul F, Waiczies S, Wuerfel J, et al.. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008, 3:e1928. 10.1371\/journal.pone.0001928","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008386.pub3","article-title":"Statins for multiple sclerosis","author":"Wang J","year":"2011","unstructured":"Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. Cochrane Database Syst Rev. 2011, CD008386. 10.1002\/14651858.CD008386.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser CM","year":"1983","unstructured":"Poser CM, Paty DW, Scheinberg L, et al.. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983, 13:227-31. 10.1002\/ana.410130302","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald WI","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, et al.. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001, 50:121-7. 10.1002\/ana.1032","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman CH","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, et al.. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011, 69:292-302. 10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000319698.40024.1c","article-title":"Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis","volume":"71","author":"Birnbaum G","year":"2008","unstructured":"Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008, 71:1390-5. 10.1212\/01.wnl.0000319698.40024.1c","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509358909","article-title":"Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy","volume":"16","author":"Lanzillo R","year":"2010","unstructured":"Lanzillo R, Orefice G, Quarantelli M, et al.. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010, 16:450-4. 10.1177\/1352458509358909","journal-title":"Mult Scler"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon \u03b2-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen PS","year":"2011","unstructured":"Sorensen PS, Lycke J, Er\u00e4linna JP, et al.. Simvastatin as add-on therapy to interferon \u03b2-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011, 10:691-701. 10.1016\/S1474-4422(11)70144-2","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri A","year":"2012","unstructured":"Tsakiri A, Kallenbach K, Fugl\u00f8 D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler. 2012, 18:72-81. 10.1177\/1352458511415452","journal-title":"Mult Scler"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway J","year":"2014","unstructured":"Chataway J, Schuerer N, Alsanousi A, et al.. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014, 383:2213-21. 10.1016\/S0140-6736(13)62242-4","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515611222","article-title":"No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon \u03b21b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)","volume":"22","author":"Lanzillo R","year":"2016","unstructured":"Lanzillo R, Quarantelli M, Pozzilli C, et al.. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon \u03b21b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016, 22:1163-73. 10.1177\/1352458515611222","journal-title":"Mult Scler"},{"key":"ref28","article-title":"Interferon \u03b2-1a and Atorvastatin in the Treatment of Multiple Sclerosis","volume":"13","author":"Ghasami K","year":"2016","unstructured":"Ghasami K, Faraji F, Fazeli M, Ghazavi A, Mosayebi G. Interferon \u03b2-1a and Atorvastatin in the Treatment of Multiple Sclerosis. Iran J Immunol. 2016, 13:16-26.","journal-title":"Iran J Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33:1444-52. 10.1212\/wnl.33.11.1444","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67194-the-effectiveness-of-statins-as-potential-therapy-for-multiple-sclerosis-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:30:10Z","timestamp":1707489010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67194-the-effectiveness-of-statins-as-potential-therapy-for-multiple-sclerosis-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,19]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.18092","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,19]]}}}